Board of Editors

Barry Hoffbrand
Former Editor
Postgraduate Medical Journal
London.,UK.
Iris Bell
Professor of Family and Community
Medicine
(Program in Integrative Medicine)
University of Arizona
Tucson, Arizona USA
Juliana Brooks
Senior Managing Director
General Resonance, LLC
Havre de Grace, Maryland USA
Effie Chow
East West Academy of Healing Arts
San Francisco, California USA
Barbara Dossey
Director, Holistic Nursing Consultants
Co-Director, Nightingale Initiative
for Global Health
Santa Fe, New Mexico USA
Bart Flick
Visiting Professor
University of Georgia
Athens, Georgia USA
Dr. Krishnaswami C.V
Retd. Prof. Clinical Medicine
Head. Diabetology Dept, VHS centre
Chennai, India.
Viktor Inyushin
Doctor of Biology
Professor at Al-Farabi Kazakh
State University Almaty
Kazakhstan

Wayne Jonas
President
Samueli Institute for Information
Biology Alexandria
Virginia USA
Brian Josephson
Nobel Laureate, Physics
Cambridge University, UK
G.B.Jain
Formerly, Chief Physician
Jassaram Hospital, New Delhi. INDIA.
Mark Mortenson
General Resonance, LLC
Havre de Grace, Maryland USA
Konstantin Korotkov
Professor of Physics
St. Petersburg State Technical
University
St. Petersburg, Russia

Vladimir Voeikov
Professor, Vice-Chairman
Faculty of Biology
Lomonosov Moscow State University
Moscow, Russia
Chris Reynolds
Wheatgrass Pty. Ltd.
PO Box 3294
Caloundra DC. Qld. 4551
Australia
Susan Lark
101, 1st Street, Suite 499
Formerly Adjunct Professor,
Stanford University Los Altos,
California USA
Andrew Weil
Director, Program of Integrative
Medicine
University of Arizona
Tucson, Arizona USA

Marc Newkirk
President, The Lightfield Foundation,
Chester, Massachusetts, USA

David Wiebers
Emeritus Professor of Neurology
Mayo Clinic
Rochester, Minnesota, USA

Marilyn Schlitz
Director of Research
Institute of Noetic Sciences
Petaluma, California USA

Gopal K Basisht MD
Consultant Rheumatologist.
1300 Edgewater Dr.
Orlando, Fl. 32804. U.S.A.

Richard Smith
Former Editor of British Medical
Journal
Editor, Cases Journal, London. UK
William Tiller
Professor Emeritus of Materials
Science
Stanford University
Payson,Arizona,USA

Type 2 Diabetes
P. R. Raghavan

Metadichol and Type 2 Diabetes: Case Report

Abstract
Background: Metadichol1,2 is a Nano emulsion of long-chain alcohols called policosanols which are found in many foods
like rice, wheat, grapes, sugar cane, apple and many others3. It acts on membrane receptors in cells throughout the body to
stimulate the immune system and inhibit a variety of disease processes, including those that result in metabolic diseases
such as diabetes, obesity and hypertension.
Methods: A 38-year-old male of middle eastern origin was diagnosed as diabetic after complaining of tiredness and bouts
of hunger. He was not on any medication and chose to be treated with Metadichol @ 10 mg per day.
Findings: Metadichol helped to lower his fasting blood sugar level from 300 mg/dl to normal in 6 weeks. His HbA1C was
reduced from 9.8% to 6.2% in 12 weeks. After 32 more months, his diabetic indicators remain normal.
Interpretation: Metadichol is safe and effective in controlling blood sugar and HbA1C levels in humans. Metadichol has
been shown to bind to the vitamin D receptor2as an inverse agonist. However, it acts more like a protean agonist ligand 4 to
increase or decrease activity depending on the system. Since Metadichol has no known negative side effects and consists
of natural components of common foods, Metadichol has the potential to serve as a novel treatment for type 2 diabetes.
Key words: Diabetes. HbA1C, Vitamin D, VDR

Introduction

hunger at his annual checkup. A routine blood test revealed

that he had high fasting glucose level of 300 mg/dl. The
patient decided against using prescription drugs and opted to

use Metadichol at 5 mg twice a day. His glucose level was

measured and monitored regularly throughout the first 12
weeks (Figures 1-8).

Globally, it is estimated that 366 million people had diabetes

in 20115. The number of people with type 2 diabetes is
rapidly increasing in every country and in some low to
middle income countries, up to 80% of people have diabetes.
India and China are the most affected countries. Diabetes
caused 4.6 million deaths in 2011. By the year 2030, it is There was rapid improvement in his condition and by week
estimated that 439 million people will have type 2 diabetes.
6, his blood glucose levels were under control. By week 12,
his HbA1C (Figure 7) had dropped from 9.8% to 6.2%. His
Type 2 diabetes is a metabolic disease that can be prevented tiredness was abated within 2 weeks of starting the regimen.
through lifestyle modification, diet control, and control of His blood was very thick and dark when he first started using
overweight and obesity. Education of the populace is still the Metadichol but by the end of week 6, his blood color was
key to control this emerging epidemic. Novel drugs are lighter and the blood flow was normal. He continued to use
being developed but despite new insight into the Metadichol at 5 mg per day and a year later, his glucose and
pathophysiology of the disease, no cure is available in sight. HbA1C remained normal.
We had previously shown the efficacy of Metadichol in
reversing type 1 diabetes6. The patient continues to produce Discussion
insulin 5 years after he stopped using Metadichol. In this
case report, we show Metadichol's potential use on patients Metadichol is a Nano emulsion of long-chain lipid alcohols
(C-26, C-28 and C-30), which are commonly known as
with Type 2 diabetes.
Policosanols. Metabolism studies in fibroblasts suggest that
very long chain fatty alcohols, fatty aldehydes, and fatty
Case Report
acids are reversibly interconverted in a fatty alcohol cycle 7,8.
A 38 years old man complained of tiredness and bouts of Since the metabolites of long chain alcohols are

Vol. 8 No.32 July 2016

Vol. 8 No.32 July 2016

Type 2 Diabetes

Type 2 Diabetes

interconverted, a single dosage even at low doses can

theoretically have lasting effects. Metadichol has a particle
size of less than 60 nm. We have shown that it binds to the
vitamin D receptor (VDR) as an inverse agonist 2. It is the
only known inverse agonist of VDR known in medical
literature.

General Manager of Micro-Sphere, Switzerland for sample

supply and helpful discussions over the past seven years,
and Dr. SC Tang, PhD, CEO of Generation100 LLC for the
collection of data from Metadichol usage on many diseases.

Calcitriol (1,25-Dihydroxy Vitamin D) is the natural ligand

for the VDR and acts as an agonist. Protean agonists act as
both positive and negative agonists on the same receptor,
depending on the degree of constitutive activity that is
present. If there is no constitutive activity, the agonist would
be a positive agonist. When constitutive activity is present,
the Protean agonist would be an inverse agonist9.
Metadichol can also act both ways, increasing insulin
secretion8 and reducing insulin in hyperinsulinemia2.
Therefore, it behaves more like a Protean agonist.

References:
1. Raghavan PR. 2014. US patent No 8.722.093
2. Raghavan PR. 2015. US Patent No 9,006,292
3. Hargrove JL, et.al. Nutritional Significance and
Metabolism of Very Long Chain Fatty Alcohols and Acids
from Dietary Waxes; Exp Biol Med (Maywood): 2004
Mar;229(3):215-26

Vitamin D is essential to the skeletal system10 and recent 4. Kenakin T. Functional Selectivity through Protean and
evidence suggests that it also plays a major role in regulating Biased Agonism: Who Steers the Ship? Mol Pharmacol:
the immune system, perhaps through the involvement in 2007; 72:1393-1402
immune responses to diseases11.
5. Zimmet P, Alberti KG, Shaw J. Global and societal
The mechanism of action of vitamin D in type 2 diabetes is implications of the diabetes epidemic. Nature:2001
thought to be mediated not only through regulation of Dec;414(6865):782-787
plasma calcium levels, which regulate insulin synthesis and
secretion, but also through a direct action on pancreatic 6. Raghavan PR. A case report of Type 1 Diabetes. Journal of
beta-cell function. Therefore, owing to its increasing the Science of Healing Outcomes: 2010; Vol 2(8/9):24
relevance, this review focuses on the role of vitamin D in the
pathogenesis of type 2 diabetes mellitus12. Metadichol also 7. Rizzo WB. Inherited disorders of fatty alcohol
shares cross-reactivity with other nuclear receptors13. This metabolism. Mol Genet Metab: 1998; 65:6373
may explain its activity against a wide range of diseases.
8. Rizzo WB, Craft DA, Dammann AL, Phillips MW. Fatty
alcohol metabolism in cultured human fibroblasts: evidence
Conclusion
for a fatty alcohol cycle. J Biol Chem: 1987;
Metadichol is a product made from agricultural waste and is 262:1741217419
a renewable resource. It has the potential to serve as an
antiviral molecule with a broad spectrum of activity, 9. Neubig RR. Missing Links: Mechanisms of Protean
particularly given that its constituents (long-chain lipid Agonism, Mol Pharmaco: 2007; l71:2001202
alcohols) are present in foods commonly consumed on a
daily basis and that it has demonstrated no toxicity at doses 10. Christakos S, Hewison M, Gardner DG, et al. Vitamin D:
of up to 5000 mg/kg 14,15. Metadichol may also serve as a Beyond bone. Ann N Y Acad Sci: 2013; 1287:45-58
preventive agent for many tropical diseases given that it
strengthens innate immunity through VDR binding. This 11. Bikle DD. Vitamin D and immune function:
could represent a first key step in preventing diseases. Understanding common pathways. Curr Osteoporos Rep:
Metadichol is ready for large scale testing in countries that 2009; 7:58-63
are ravaged by diabetes such as India and China. Once
proven on large populations, Metadichol could be used as a 12. Palomer X, Gonzlez-Clemente JM, Blanco-Vaca F,
preventive nutritional supplement and a cheaper but more Mauricio D. Role of vitamin D in the pathogenesis of type 2
effective substitute for prescription drugs that have been diabetes mellitus. Diabetes Obes Metab: 2008
largely ineffective and have many adverse side effects that Mar;10(3):185-97
add to higher healthcare costs.
13. Raghavan PR. unpublished work
Acknowledgements
14. Alemn CL, Ms R, Hernndez, et al. A 12-month study
The author would like to thank Dr. Michel Muller, PhD, of policosanol oral toxicity in Sprague Dawley rats. Toxicol

Vol. 8 No.32 July 2016

Lett; 1994; 70:77-87; Alemn, C.L, Ms Ferreiro, et al. 15. Aleman C.L, Puig MN, ElN, E.C., et al., Carcinogenicity
Carcinogenicity of policosanol in Sprague Dawley rats: A of policosanol in mice. An 18-month study. Food Chem
24-month study. Teratog Carcinog Mutagen 1994; 14:239
Toxicol: 1995: 33, 573-8

Figure 1: Daily Fasting Glucose level before breakfast

Figure 2: Glucose level 2 hours after breakfast

Vol. 8 No.32 July 2016

Type 2 Diabetes

Type 2 Diabetes

Figure 3: Glucose level before lunch

Figure 6: Glucose level 2 hours after dinner

Figure 4: Glucose level 2 hours after lunch

Figure 7: HbA1C levels at baseline and at day 84

Figure 5: Glucose level before dinner

Vol. 8 No.32 July 2016

Vol. 8 No.32 July 2016

Type 2 Diabetes

Note: Glucose units are mg/dl

Figure 8: Glucose level comparison at baseline, average first 41 days and average days 42-84

Dr. P. R. Raghavan
Nanorx Inc.
P.O. Box 131
Chappaqua, NY 10514
USA
Email: raghavan@nanorxinc.com

Cover: Metadichol: Metadichol is found safe and effective in controlling blood sugar and
HbA1C levels in human beings. It binds to vitamin D receptor2 as an inverse agonist. It acts
more like a protean agonist ligand 4 to increase or decrease activity depending on the system.
Since Metadichol has no negative side effects and consists of natural components of common
foods, it has the potential to serve as a novel treatment for type 2 diabetes.

10 Vol. 8 No.32 July 2016

Vol. 8 No.32 July 2016 11